Quantification of Plasma miRNA-150 Across HIV-Infected Cohorts and its Correlation with CD4 and CD8 T-Cell Counts
Annals of International Medical and Dental Research · 2026-06 · 12 (3) · 55-62
DOI: 10.53339/aimdr.2026.12.3.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of International Medical and Dental Research, 2026-06. Verfasst von Nusrat Fatema und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Plasma microRNAs have emerged as potential biomarkers in HIV infection, but the role of miRNA-150 across clinically stratified HIV groups remains uncertain. Aim of the study: To quantify plasma miRNA-150 among different groups of HIV-infected patients and to evaluate its correlation with CD4 and CD8 T-lymphocyte count.
Methods
This cross-sectional study used archived plasma samples from HIV-1-infected adults preserved at the Department of Virology, Bangladesh Medical University, Bangladesh from July, 2024 to June, 2025. Participants were categorized into four protocol-defined groups: ART naïve with CD4 count
Zitieren
APA
Fatema, N., Khan, S., Munshi, S. U., Tania, Z. F., & Tabassum, S. (2026). Quantification of Plasma miRNA-150 Across HIV-Infected Cohorts and its Correlation with CD4 and CD8 T-Cell Counts. Annals of International Medical and Dental Research, 12(3), 55-62. https://doi.org/10.53339/aimdr.2026.12.3.8
Vancouver
Fatema N, Khan S, Munshi SU, Tania ZF, Tabassum S. Quantification of Plasma miRNA-150 Across HIV-Infected Cohorts and its Correlation with CD4 and CD8 T-Cell Counts. Annals of International Medical and Dental Research. 2026;12(3):55-62. doi:10.53339/aimdr.2026.12.3.8
BibTeX
@article{Fatema2026,
author = {Fatema, Nusrat and Khan, Shafinaz and Munshi, Saif Ullah and Tania, Zannatul Ferdous and Tabassum, Shahina},
title = {Quantification of Plasma miRNA-150 Across HIV-Infected Cohorts and its Correlation with CD4 and CD8 T-Cell Counts},
journal = {Annals of International Medical and Dental Research},
year = {2026},
volume = {12},
number = {3},
pages = {55--62},
doi = {10.53339/aimdr.2026.12.3.8}
}
EUVIMED